ICD-10-CM · Multi-region

M10.39

Gout caused by renal impairment affecting multiple joint sites simultaneously — classified under secondary gout with a mandatory 'code first' instruction for the underlying renal disease.

Verified May 8, 2026 · 5 sources ↓

Status
Billable
Chapter
13
Related CPT
12
Region
Multi-region
Drawn from CDCICD10DataAAPCIcd10beIcdcodes

Documentation tips

What should appear in the chart to support M10.39.

Source · Editorial brief grounded in 5 cited references ↓

  • Name every affected joint explicitly (e.g., 'gouty arthritis involving bilateral knees and right first MTP') so 'multiple sites' is defensible on audit.
  • Document the underlying renal diagnosis by type and stage (e.g., CKD stage 3b due to hypertensive nephrosclerosis) — the 'Code First' rule requires the renal disease code to appear before M10.39 on the claim.
  • Distinguish acute gout flare from chronic tophaceous gout in the note; if tophi are present, the correct category is M1A, not M10.
  • Record serum uric acid level and, when performed, synovial fluid analysis or imaging findings (dual-energy CT, ultrasound double-contour sign) supporting urate crystal deposition.
  • Note any concurrent manifestations that trigger additional codes — urinary tract calculi (N22), glomerular disease (N08) — if the provider documents them as present.

Related CPT procedures

Procedure codes commonly billed with M10.39. Linking the right diagnosis to the right procedure is what establishes medical necessity.

Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis

20600 $56.11
Needle aspiration and/or injection of a small joint or bursa — such as a finger or toe joint — performed without ultrasound guidance.
20604 $87.18
Arthrocentesis, aspiration and/or injection of a small joint or bursa (e.g., fingers, toes) performed with ultrasound guidance, including permanent image recording and reporting.
20605 $57.12
Aspiration and/or injection of an intermediate joint or bursa — such as the wrist, elbow, ankle, acromioclavicular joint, or olecranon bursa — performed without ultrasound guidance.
20606 $94.19
Aspiration and/or injection of an intermediate joint or bursa — such as the wrist, elbow, ankle, acromioclavicular, temporomandibular, or olecranon bursa — performed with real-time ultrasound guidance and permanent image recording and reporting.
20610 $68.81
Aspiration and/or injection of a major joint or bursa (shoulder, hip, knee, or subacromial bursa) performed without ultrasound guidance.
20611 $104.21
Aspiration or injection of a major joint or bursa performed under real-time ultrasound guidance, with permanent image documentation.
73564 $49.43
Radiologic examination of the knee consisting of four or more views, including oblique and tunnel projections, for a complete diagnostic workup.
73562 $42.42
Three-view radiographic examination of the knee joint, capturing anteroposterior, lateral, and a third angle such as a sunrise or oblique view.
99213 $95.19
Established patient office or outpatient visit requiring 20–29 minutes of total time or low-complexity medical decision-making.
99214 $135.61
Office visit for an established patient requiring moderate-complexity medical decision making (MDM), or 30–39 minutes of total provider time on the date of service.
99215 $192.39
Highest-level office or outpatient E/M visit for an established patient, qualifying via high-complexity medical decision making or 40–54 minutes of total provider time on the date of service.
77072 View procedure details

Common coding pitfalls

The recurring mistakes coders make with M10.39 and adjacent codes.

Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓

  • Failing to sequence the renal disease code first violates the M10.3 'Code First' instruction and can result in claim denial or medical necessity audit failure.
  • Using M10.39 for chronic gout with tophi — that presentation requires M1A.39X0 (without tophus) or M1A.39X1 (with tophus) from the chronic gout category.
  • Defaulting to M10.39 when only one joint is involved — use the site-specific M10.3x subcodes (shoulder, elbow, wrist, hand, hip, knee, ankle/foot, vertebrae) when a single region is documented.
  • Confusing M10.39 (renal impairment etiology) with M10.49 (other secondary gout, multiple sites) — the etiology must be confirmed as renal impairment in the clinical documentation.
  • Omitting additional manifestation codes (e.g., N22 for uric acid kidney stones) that the 'Use Additional Code' instruction at the M10 category level requires when those conditions are documented.

Clinical context

Source · Editorial summary grounded in 5 cited references ↓

M10.39 applies when a patient presents with an acute gout attack (or active gout flare) attributable to renal impairment and the involvement spans multiple anatomic sites — for example, simultaneous gouty arthritis of the knee, ankle, and wrist in the setting of chronic kidney disease. This is a secondary gout code under the M10.3 subcategory, meaning the kidneys' reduced urate clearance is the documented etiology driving urate crystal deposition.

The ICD-10-CM tabular carries a 'Code First' instruction at the M10.3 level: you must sequence the associated renal disease (e.g., N18.3 for CKD stage 3) before M10.39. Skipping that sequencing is an audit trigger and misrepresents the clinical picture. The M10 category also carries 'Use Additional Code' instructions for associated manifestations such as autonomic neuropathy (G99.0), urinary calculi (N22), and glomerular disorders (N08) — apply these when documented.

Do not use M10.39 for chronic tophaceous gout; that belongs to M1A.39X0 (without tophus) or M1A.39X1 (with tophus). M10 covers acute gout, gout attacks, and gout flares. If only a single joint or region is involved, drop to the site-specific M10.3x codes (e.g., M10.361/M10.362 for right/left knee, M10.371/M10.372 for right/left ankle and foot). Use M10.39 only when the documented clinical picture genuinely involves multiple distinct sites.

Sibling codes

Other billable codes under M10.3 (laterality / anatomic variants).

Frequently asked questions

Source · Generated from the editorial pipeline, verified against 5 cited references ↓

01Which code goes first on the claim — M10.39 or the renal disease code?
The renal disease code (e.g., N18.3 for CKD stage 3) must be sequenced first. The ICD-10-CM tabular places a 'Code First associated renal disease' instruction at the M10.3 subcategory level. M10.39 is the secondary listed diagnosis.
02Can I use M10.39 if the patient has tophi?
No. Tophaceous gout is classified under chronic gout (M1A). Use M1A.39X1 for chronic gout due to renal impairment at multiple sites with tophus, or M1A.39X0 without tophus. M10 is reserved for acute attacks and flares.
03What qualifies as 'multiple sites' for M10.39?
The ICD-10-CM does not define a minimum number, but 'multiple sites' means two or more distinct anatomic regions are involved in the same encounter. If only one joint or body region is affected, use the site-specific M10.3x subcode instead.
04Is M10.39 valid for billing in FY2026?
Yes. M10.39 is a billable, specific code effective October 1, 2025 under the FY2026 ICD-10-CM edition. It has been valid and unchanged since the ICD-10-CM implementation in 2015.
05What additional codes should I consider alongside M10.39?
The M10 category instructs coders to use additional codes for associated manifestations when documented: autonomic neuropathy (G99.0), urinary calculi (N22), cardiomyopathy (I43), glomerular disorders (N08), and disorders of the iris and ciliary body (H22), among others.
06How does M10.39 differ from M10.49 (other secondary gout, multiple sites)?
Etiology is the distinction. M10.39 is used when renal impairment is the documented cause of urate overproduction or underexcretion. M10.49 covers secondary gout from other causes, such as medications or hematologic disorders. The provider must document the specific secondary cause.
07Do I need imaging to support M10.39?
Imaging is not required to report the code, but documentation of joint findings — whether from synovial fluid analysis, dual-energy CT, ultrasound, or plain radiograph — strengthens medical necessity. Serum uric acid level and clinical presentation are often the primary supporting evidence.

Sources & references

Editorial content was developed using the following public sources. Last verified May 8, 2026.

  1. 01CDC ICD-10-CM Tabular List 2026 (FY2026, effective Oct 1, 2025)
  2. 02
    icd10data.com
    https://www.icd10data.com/ICD10CM/Codes/M00-M99/M05-M14/M10-/M10.39
  3. 03
    aapc.com
    https://www.aapc.com/codes/icd-10-codes/M10.39
  4. 04
    icd10be.health.belgium.be
    https://icd10be.health.belgium.be/default.php#!tabular/2025/M10.39/1
  5. 05
    icdcodes.ai
    https://icdcodes.ai/icd10/M10.39

Mira AI Scribe

Mira captures the joint-by-joint distribution of the flare, the documented renal diagnosis and CKD stage, serum uric acid, and any imaging or synovial fluid findings — preventing the most common audit flags: missing renal disease as the primary sequenced code, underdocumented site involvement, and erroneous use of M10.39 for chronic tophaceous gout that belongs in the M1A category.

See how Mira captures M10.39 documentation

Related ICD-10 codes

Ready?

Ready to transform your orthopedic practice?

See how orthopedic practices are running documentation, billing, and operations on a single voice-first platform.

Get started for free